glp-1 agonist eli lilly Abu Dhabi, United Arab Emirates – and Company (NYSE: LLY) today reported positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral receptor agonist, in Managing obesity and type 2

PMID: 33460513

Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis Luis M

Here is an honest look at where the science stands as of early 2026: Animal studies are promising

Cell Physiol Biochem 44:763777

Skin density and hair quality improvements are most pronounced at the 12 to 16-week mark

The review also notes that GLP-1 medicines reduce complications in conditions such as obstructive sleep apnea (OSA), expanding their cardiometabolic relevance